New Agreement to Boost Clinical Trial Participation for BRANY
BRANY joins other select organizations that have received the same designation from Quintiles across the USA, Europe, Africa and Asia. BRANY is committed to excellence in the conduct of clinical research, and the company supports Quintiles’ vision to bring people and knowledge together for a healthier world. BRANY’s network of highly qualified and experienced researchers and track record in working with community and academic study sites will accelerate the development of new therapies.
“BRANY is committed to excellence in clinical research and improving patient care , says Kimberly Irvine, Executive Vice President of Operations at BRANY. “This alliance will provide our leading investigators and hospitals with significant opportunities to access industry-sponsored clinical trials. We are excited to be working with Quintiles to bring new clinical trials to our sites and patients.”
BRANY’s Smart Start 60 increases efficiencies and sustainability among their community and academic study sites to expedite clinical research timelines. These efficiencies translate to real-life benefits as clinical trials are concluded on or ahead of schedule to advance treatments for unmet medical needs in a cost-effective way that does not jeopardize the quality standards of the of research.
“We have been working with BRANY for 14 years and are continuously impressed with the calibre of their investigator network and the quality of their research,” said Lindy Jones, Senior Vice President, Integrated Site Services, Quintiles. “BRANY consistently sets and meets aggressive start-up timelines. They are able to conduct studies in both the hospital and community settingbroadening opportunities for patients to participate in studies. We welcomeBRANY as the newest Prime Site and look forward to continued success together.”
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025